News

The divestment agreement was first announced in October 2019. The transaction includes approximately 30 select prescription pharmaceutical and OTC products. These products will continue to be made available

Forty Seven is engaged in the development of novel checkpoint therapies to stimulate macrophages for the treatment of cancer. The deal is expected to strengthen Gilead’s immuno-oncology research

In this connection, the FDA approved the company’s investigational new drug (IND) application for HBM4003. The biopharma company said that the US clinical study follows an initial trial

The Company’s primary focus will be on the development of CH5126766 (VS-6766), its RAF/MEK inhibitor, in combination with defactinib, its focal adhesion kinase (FAK) inhibitor, for the treatment

IXINITY® is an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by

Last September, the company secured approval from the US Food and Drug Administration (FDA) for nintedanib to slow the rate of decline in pulmonary function in adults living

Separately, the Agency’s Office of Orphan Products Development granted HBM9167 Orphan Drug Designation (ODD) for the use in treating NPC. “Nasopharyngeal cancer is a tumor type for which

Under the terms of strategic alliance, Boehringer Ingelheim gains access to Trutino’s ODC platform technology for the generation and development of up to three new ODC candidates. This

The regulator has accepted the application for the use of once-daily and single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) to treat asthma in adults. Trelegy Ellipta